Blood and Lymphatic Cancer: Targets and Therapy (Apr 2022)
Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma
Abstract
Justin J Kuhlman,1 Muhamad Alhaj Moustafa,2 Liuyan Jiang,3 Jing Wang,1 Vivek Gupta,4 Han W Tun2 1Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA; 2Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA; 3Department of Pathology and Laboratory Medicine, Mayo Clinic, Jacksonville, FL, USA; 4Department of Radiology, Mayo Clinic, Jacksonville, FL, USACorrespondence: Han W Tun, Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road S, Jacksonville, FL, 32224, USA, Tel +1 904-953-2000, Email [email protected]: Primary central nervous system lymphoma (PCNSL) carries a dismal prognosis in elderly patients above 70 years of age with a median overall survival of 6 months. Novel therapeutic agents are urgently needed to improve survival outcomes in this age group. We describe the clinical presentation, diagnostic workup, and treatment outcome in two 80-year-old patients diagnosed with PCNSL who were treated with ibrutinib therapy. Both patients remain in complete remission following treatment with ibrutinib therapy. One patient is currently 4 years and the other is 2 years and 9 months from the time of initial diagnosis. We suggest that ibrutinib therapy has significant therapeutic activity against PCNSL in the newly diagnosed setting and should be evaluated in a clinical trial as part of front-line therapy, especially in elderly patients.Keywords: newly diagnosed primary central nervous system lymphoma, ibrutinib, elderly adults, relapsed/refractory primary central nervous system lymphoma, clinical outcomes
